

Press Release

for Immediate Release

Granules India reports Income from operations at INR 997 Cr up 18% YoY, EBITDA at INR 174 Cr, EBITDA Margin at 17%; PAT at INR 101 Cr.

Hyderabad, India, February 8, 2022: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and nine months ended December 31, 2021.

Financial Highlights (All numbers in INR Cr., except Margins)


CONSOLIDATED FINANCIALS	Q3FY22	Q3FY21	Growth (YoY)
Income from Operations	997	845	18%
Operating Profit	174	212	(18%)
Operating Profit Margin	17%	25%	
PAT	101	147	(31%)
Net Profit Margin	10%	17%	

Financial and Business Highlights for Q3FY22

- Revenue for Q3FY22 stood at INR 997 Crs, growth of 18% YoY.
- FD segment grew by 8%, PFI grew by 32% and API 24% when compared to YoY.
- Increase in Paracetamol across all the segments by INR 108 Cr and increase in other molecules by INR 56 Crs in view of steady market capture by newly launched molecules.
- For the consecutive two quarters, revenue share of other molecules maintained at 19%.
- Revenue from Europe increased to 24.5% when compared to 18.6% YoY on account of increase in selling prices for Paracetamol.
- The overall gross margin recorded is lower in % terms due to change in Segment mix in the total revenue. Share of Finished dosage has come down from 57% in Q2 to 46% in Q3 due to higher inventory build-up at USA and year end.
- EBITDA stood at INR 174 Crs, down by 17.9% YoY. EBITDA margins stood at 17.4% compared to 25.1%. PAT at INR 101 Cr, down by 31.3%, driven by reduction in Gross margin and increase in Freight cost by INR 29 Crs on account of shortage of containers and increase in R&D cost by INR 13 Crs as part of our future growth strategy.
- During the quarter we filed two ANDA, two Canadian Dossiers, one US DMF, one CEP and received three ANDA approvals.
- The Board of Directors has declared its third interim dividend of 25 paise per equity share of INR 1/- each.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “I am pleased to share that we are slowly getting back to the normal as is evident from the revenue growth which came in despite the continuing disruptions and challenging environment such as raw material price increase, unstable supply from China and PAP supply constraints. We expect the situation to improve in coming quarters and remain focused on execution and agile to the market opportunities. We at Granules are now ready to take a leap to transform our business to the next level. We are strengthening management capabilities and are investing in R&D infrastructure, scientific talent, and partnerships in science & technology which will lead to sustainability, leadership, backward integration and focus on quality of our portfolio. Our initiatives will bring in the triple bottom line in the form of social, environmental, and financial advantages resulting in a greater stakeholder’s value.”

Segmental, Molecule and Geographical Mix for Q3 FY22 (All numbers in INR Cr)



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, US and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Contacts:

Krishna Raghunathan
040-69043573
VP – Finance and Investor Relations
krishna.raghunathan@granulesindia.com

Chaitanya Tummala
040-69043614
Company Secretary
chaitanya.tummala@granulesindia.com

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.